SEPN Septerna Inc: Rasio rega marang prakiraan pendapatan
Septerna Inc is accelerating the development of immunological agents via its Native GPCR robotic system. The projected P/S trend helps align market capitalization with expected revenue, where 20.60 is established as the baseline value. An innovative approach to GPCR targets strengthens the company's authority within the scientific community. A neutral geopolitical backdrop and the business's humanitarian profile minimize external risks for investors.
Rincian analitis perusahaan Septerna Pharma (SEPN)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Septerna Inc|SEPN - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Septerna Inc|SEPN - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Septerna Pharma|SEPN - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Septerna|Rasio cepet septerna.com
- rincian asil keuangan lan kelipatan valuasi:
SEPN - Bathi resik|Bathi mangsa ngarep Septerna Inc|SEPN - Nilai perusahaan marang bathi resik|Pangali Forward P/E Septerna Corp|SEPN - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Septerna Pharma|SEPN - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Septerna|SEPN - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan septerna.com|SEPN - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Septerna Inc
- rincian pendapatan lan dodolan:
Analisis wiwitan perusahaan:SEPN (Septerna)
Septerna Inc (SEPN) maintains stability by retaining leading GPCR receptor specialists through a stock option system. The forward P/S multiple daily compares market capitalization with expected revenue, reflecting the business value trend. Extremes on this chart signal a disconnect between model viability and capital risk, allowing investors to determine the asset's fair value based on the commercialization prospects of its developments.
Pesaing wigati
Multiplikator Forward P/S ARGX (argenx)|BioNTech Inc. (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABVX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake ADMA Corp ADMA|PTGX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep immunovant.com (IMVT)|Rasio rega marang prakiraan pendapatan Kiniksa|Grifols SA - Rega mangsa ngarep marang pendapatan|Multiplikator forward rega marang pendapatan ADPT (Adaptive Biotechnologies Corp)|Rasio rega marang pendapatan sing dikarepake CLDX|Multiplikator Forward P/S AUPH (Aurinia Pharmaceuticals)|biocryst.com (BCRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|VERA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp (PHVS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan ABCL|TRML (Tourmaline Bio, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S precigen.com|Multiplikator forward rega marang pendapatan PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Rega forward marang dodolan|Multiplikator Forward P/S UPB (Upstream Bio Corp)|Rasio kapitalisasi marang dodolan sing dikarepake Zenas Corp (ZBIO)|IMNM - Rasio rega marang prakiraan pendapatan|GOSS (gossamerbio.com) - Kapitalisasi marang prakiraan pendapatan|KALV: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pieris Pharma|Rasio rega marang prakiraan pendapatan Savara Corp|Rigel Corp (RIGL) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ANAB|ATXS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Rega mangsa ngarep marang pendapatan|JBIO - Rasio rega marang prakiraan pendapatan|ACRS (Aclaris Therapeutics, Inc) - Kapitalisasi marang prakiraan pendapatan|Kyverna Therapeutics (KYTX) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Multiplikator Forward P/S|VTYX: Rega forward marang dodolan|Multiplikator Forward P/S THTX|Multiplikator Forward P/S Avalo Therapeutics Inc (AVTX)|Rasio rega marang prakiraan pendapatan Eledon Pharmaceuticals ELDN|Rega forward marang dodolan AGEN|CLYM - Rasio rega marang prakiraan pendapatan|Zura Bio Ltd (ZURA) - Multiplikator forward rega marang pendapatan|ATYR: Multiplikator Forward P/S|Adagene Inc. (ADAG) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan IMA|STTK: Rega forward marang dodolan|Multiplikator Forward P/S EQ|Rasio kapitalisasi marang dodolan sing dikarepake connectbiopharm.com|Rasio rega marang prakiraan pendapatan Immunic IMUX|ATRA - Multiplikator forward rega marang pendapatan|IFRX - Rasio rega marang prakiraan pendapatan|x4pharma.com (XFOR) - Multiplikator forward rega marang pendapatan|ACET (adicetbio.com) - Multiplikator forward rega marang pendapatan|Celularity (CELU) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan INmune Bio Corp|Kapitalisasi marang prakiraan pendapatan BRNS (Barinthus Biotherapeutics Corp)|Multiplikator Forward P/S KZR|SABS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Akari Therapeutics Plc AKTX|Rasio kapitalisasi marang dodolan sing dikarepake Enlivex Therapeutics Ltd (ENLV)|Q32 Bio Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GeoVax Corp|Edesa Biotech, Inc. (EDSA) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan IBIO (ibioinc.com)|Multiplikator forward rega marang pendapatan CARM|XTLB (XTL Biopharmaceuticals Ltd) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S BOLT|HCWB - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aptevo Therapeutics Inc. APVO|Rega forward marang dodolan AIM|ADTX - Rasio rega marang prakiraan pendapatan|GRI (GRI Bio Inc) - Kapitalisasi marang prakiraan pendapatan|XRTX: Multiplikator Forward P/S|Vyome Therapeutics (HIND) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan REVB|INDP: Rega forward marang dodolan|Multiplikator Forward P/S SCNI|Rasio kapitalisasi marang dodolan sing dikarepake calcimedica.com|Rasio rega marang prakiraan pendapatan Affimed N.V. AFMD|ALLK: Kapitalisasi marang prakiraan pendapatan|HOOKIPA - Multiplikator Forward P/S|IGM Biosciences, Inc. (IGMS) - Multiplikator forward rega marang pendapatan|iTeos Therapeutics, Inc. (ITOS) - Rasio rega marang prakiraan pendapatan|OCEA - Rasio kapitalisasi marang dodolan sing dikarepake|TCBP (TC BioPharm (Holdings) PLC) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Third Harmonic Bio Inc THRD
